Exploration of isoxazole analogs: Synthesis, COX inhibition, anticancer screening, 3D multicellular tumor spheroids, and molecular modeling.

Authors

Mohammed Hawash, Samer Abdallah, Mahmoud Abudayyak, Yarob Melhem, Mohammed Abu Shamat, Meera Aghbar, Irfan Çapan, Murad Abualhasan, Anil Kumar, Michał Kamiński, Tomasz Góral, Paulina Maria Dominiak, Shorooq Sobuh

Published in

European journal of medicinal chemistry. Volume 271. Pages 116397. Apr 15, 2024. Epub Apr 15, 2024.

Abstract

In this study, a new series of Isoxazole-carboxamide derivatives were synthesized and characterized via HRMS, ¹H-, ¹³C_APT-NMR, and MicroED. The findings revealed that nearly all of the synthesized derivatives exhibited potent inhibitory activities against both COX enzymes, with IC₅₀ values ranging from 4.1 nM to 3.87 μM. Specifically, MYM1 demonstrated the highest efficacy among the compounds tested against the COX-1, displaying an IC₅₀ value of 4.1 nM. The results showed that 5 compounds possess high COX-2 isozyme inhibitory effects with IC₅₀ value in range 0.24-1.30 μM with COX-2 selectivity indexes (2.51-6.13), among these compounds MYM4 has the lowest IC₅₀ value against COX-2, with selectivity index around 4. Intriguingly, this compound displayed significant antiproliferative effects against CaCo-2, Hep3B, and HeLa cancer cell lines, with IC₅₀ values of 10.22, 4.84, and 1.57 μM, respectively, which was nearly comparable to that of doxorubicin. Compound MYM4 showed low cytotoxic activities on normal cell lines LX-2 and Hek293t with IC₅₀ values 20.01 and 216.97 μM respectively, with safer values than doxorubicin. Furthermore, compound MYM4 was able to induce the apoptosis, suppress the colonization of both HeLa and HepG2 cells. Additionally, the induction of Reactive oxygen species (ROS) production could be the mechanism underlying the apoptotic effect and the cytotoxic activity of the compound. In the 3D multicellular tumor spheroid model, results revealed that MYM4 compound hampered the spheroid formation capacity of Hep3B and HeLa cancer cells. Moreover, the molecular docking of MYM4 compound revealed a high affinity for the COX2 enzyme, with energy scores (S) -7.45 kcal/mol, which were comparable to celecoxib (S) -8.40 kcal/mol. Collectively, these findings position MYM4 as a promising pharmacological candidate as COX inhibitor and anticancer agent.

PMID:
38626522
Bibliographic data and abstract were imported from PubMed on 17 Apr 2024.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.